Carl Zeiss Meditec AG
General ticker "CZMWF" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $3.4B (TTM average)
Carl Zeiss Meditec AG does not follow the US Stock Market performance with the rate: -20.9%.
Estimated limits based on current volatility of 0.3%: low 39.91$, high 40.14$
Factors to consider:
- Company pays dividends (annually): last record date 2026-03-30, amount 0.63$ (Y1.58%)
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [35.46$, 67.32$]
- 2026-09-30 to 2027-09-30 estimated range: [35.54$, 67.03$]
Financial Metrics affecting the CZMWF estimates:
- Positive: with PPE of 23.5 at the end of fiscal year the price was neutral
- Positive: 7.80 < Operating profit margin, % of 10.02
- Positive: 58.56 < Shareholder equity ratio, % of 62.19 <= 69.38
- Negative: Return on assets ratio (scaled to [-100,100]) of 4.01 <= 5.14
- Negative: Industry operating cash flow per share per price (median), % of 1.48 <= 3.66
- Negative: negative Industry operating income (median)
- Negative: Industry inventory ratio change (median), % of 1.54 > 1.15
- Positive: 4.90 < Operating cash flow per share per price, % of 6.36
- Negative: -3.92 < Inventory ratio change, % of -2.36
Short-term CZMWF quotes
Long-term CZMWF plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | €2,089.30MM | €2,066.13MM | €2,227.64MM |
| Operating Expenses | €1,762.16MM | €1,944.78MM | €2,004.33MM |
| Operating Income | €327.14MM | €121.35MM | €223.32MM |
| Non-Operating Income | €85.43MM | €119.52MM | €-29.43MM |
| Interest Expense | €1.92MM | €29.42MM | €26.62MM |
| R&D Expense | €349.28MM | €343.09MM | €326.27MM |
| Income(Loss) | €412.56MM | €240.87MM | €193.89MM |
| Taxes | €120.56MM | €60.71MM | €51.55MM |
| Net Income(Loss)* | €290.40MM | €178.73MM | €141.21MM |
| Stockholders Equity | €2,159.45MM | €2,041.70MM | €2,116.51MM |
| Inventory | €519.62MM | €536.16MM | €496.98MM |
| Assets | €3,032.92MM | €3,393.20MM | €3,403.37MM |
| Operating Cash Flow | €250.86MM | €247.32MM | €246.26MM |
| Capital expenditure | €113.86MM | €152.20MM | €46.23MM |
| Investing Cash Flow | €-110.98MM | €-412.31MM | €-106.81MM |
| Financing Cash Flow | €-135.09MM | €176.25MM | €-127.70MM |
| Earnings Per Share** | €3.25 | €2.01 | €1.61 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.